Hemogenyx Pharmaceuticals Says FDA Accepted Plans to Address Leukemia Treatment Concerns
By Anthony O. Goriainoff
Hemogenyx Pharmaceuticals said the U.S. Food and Drug Administration has accepted its plans to address the agency's concerns over its leukemia treatment product candidate.
The London-listed biopharmaceutical group--that develops new therapies and treatments for blood diseases--said Thursday it had submitted a detailed plan for its HEMO-CAR-T investigational new drug, or IND, which was supported by laboratory tests to address the FDA's concerns.
On July 10, the company said the FDA was concerned with the splicing that occurs during the manufacturing of the lentivirus used in its acute myeloid leukemia treatment product.
"We are now working hard to complete the schedule of work set out in the plan and to resubmit the IND as expeditiously as possible in order to move forward with clinical trials of HEMO-CAR-T," Chief Executive Vladislav Sandler said.
Shares at 0734 GMT were up 0.02 pence, or 1.5%, at 1.68 pence.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
September 14, 2023 03:56 ET (07:56 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
Is the Era of Volatility-Suppressing Policies Possibly Over?
-
5 Undervalued Stocks That Crushed Earnings for Q1 2024
-
What Does Nvidia’s Stock Split Mean for Investors?
-
After Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Baidu Stock a Buy, a Sell, or Fairly Valued?
-
Why Stocks Are Hitting Record Highs—and What Could Send Them Back to Earth
-
2 Wide-Moat Stocks to Consider
-
Live Nation: Breakup Sought by Department of Justice Probably Wouldn’t Affect Fair Value Much
-
After Earnings, Is Applied Materials Stock a Buy, Sell, or Fairly Valued?
-
The Best Energy Stocks to Buy
-
Snowflake Earnings: Mixed News, But Signs of Stability
-
Nvidia Earnings: AI Demand Smashes Expectations Again
-
After Earnings, Is Walmart Stock a Buy, a Sell, or Fairly Valued?
-
Target Earnings: Margins Hold Up, but Top Line Constrained by Weak Discretionary Spending